More information: Laura Martinez-Verbo et al, PVR (CD155) epigenetic status mediates immunotherapy response in multiple myeloma, Leukemia (2024). DOI: 10.1038/s41375-024-02419-z Provided by Josep ...

The molecular pathogenesis of cancers, including multiple myeloma, is deeply related not only to genetic alterations but also to epigenetic changes. The epigenetic regulator KDM5 family proteins are ...

The epigenetic status of the PVR receptor might be a good prognostic marker for multiple myeloma, according to the latest research from the Cancer Epigenetics Lab led by Dr. Manel Esteller at the ...

Multiple myeloma is a type of blood cancer that appears mainly after the age of sixty. Its incidence, therefore, increases with the aging of the population. In this pathology, the bone marrow, the ...

While it trails Johnson & Johnson’s Tecvayli, Regeneron still hopes Lynozyfic can differentiate in terms of dosing ...

The findings contradict previous research suggesting high-risk patients with multiple myeloma were more likely to have a ...

Given the advantages over its rivals, Regeneron is hopeful its bispecific antibody will become the new standard of care for ...

The FDA granted accelerated approval of linvoseltamab-gcpt for certain patients with multiple myeloma.Specifically, the ...

A ground-breaking study has revealed crucial insights into the role of the histone methyltransferase NSD2 and its epigenetic target PKC-alpha in causing t(4;14) translocated multiple myeloma (MM ...

The Food and Drug Administration (FDA) has granted accelerated approval to Lynozyfic™ (linvoseltamab-gcpt) for the treatment of adult patients with ...

More information: Laura Martinez-Verbo et al, PVR (CD155) epigenetic status mediates immunotherapy response in multiple myeloma, Leukemia (2024). DOI: 10.1038/s41375-024-02419-z Journal ...

Multiple myeloma is a type of blood cancer that appears mainly after the age of sixty. Its incidence, therefore, increases with the aging of the population. In this pathology, the bone marrow, the ...